TAIPEI-EXCHANGE
8.6.2022 10:02:10 CEST | Business Wire | Press release
The Taipei Exchange (TPEx), has successfully built an efficient multi-tiered fund-raising platform to foster the growth of innovative companies within the Taiwan capital market while also focusing on Environmental, Social and Governance (ESG) practices.
Support for Innovation
Along with a Mainboard of well-established companies, TPEx provides an Emerging Stock market, which includes Emerging Stock board and Pioneer Stock board, for companies prior to IPO, and the Go Incubation Board for Startup and Acceleration Firms. This multi-tiered structure aims to support the growth of enterprises through various stages of their development.
In line with Taiwan government policies, TPEx has been devoted to fostering innovative industries, high-tech industries, and small and medium-sized enterprises (SMEs), thus driving the momentum of Taiwan’s economy. Since its establishment 28 years ago, TPEx has assisted more than 2,300 public companies to gain access and contribute to the Taiwan capital market.
Environmental, Social and Governance (ESG) Practices
While providing a convenient mechanism for fundraising, TPEx also assists listed companies in setting their sustainable operations and ESG practices in response to the impact of climate change and international attention to the sustainability issue. As The European Union’s (EU’s) proposed new directive on corporate sustainability reporting (CSRD) is planned to come into effect in January 2023, TPEx has long been engaged in enhancing ESG information transparency, including requiring listed companies to prepare Sustainability reports in accordance with GRI Standards and strengthening the disclosure of Sustainability Reporting with reference to international norms under TCFD and SASB.
TPEx has also made efforts to publish relevant information and guidelines to assist listed companies in strengthening ESG-related disclosure. The rate of listed companies that prepared sustainability reports for 2020 was around 20% and according to the "CG WATCH 2020 Report” from the Asian Corporate Governance Association (ACGA), Taiwan’s concerted effort over the past two years to enhance its CG ecosystem has moved it from fifth to fourth position.
In order to deepen sustainable growth, TPEx has strengthened the function of the board of directors for listed companies and continues to expand the scope of TPEx-listed companies that are required to prepare Sustainability reports. Companies are encouraged to enhance communications with stakeholders, and from June 2023, TPEx-listed companies will also be required to appoint a Chief Governance Officer.
To meet the needs for ESG investing and sustainable financing globally, TPEx has been promoting diversified ESG investment products and responsible investment. TPEx has launched several sustainability-themed indexes to steer market funds toward investments that address climate change and environmental sustainability. The Chairman of TPEx, Philip Chen, stated that, “TPEx commits to upholding ESG values to strengthen our core businesses. TPEx will continue to promote capital raising functionality, innovative and sustainable related products, information transparency, and efficient fair-trading mechanisms; building a vibrant and innovative world-class capital market.”
For more information about the Taipei Exchange, please visit: https://www.tpex.org.tw/web/index.php?l=en-us
View source version on businesswire.com: https://www.businesswire.com/news/home/20220608005017/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom